Somewhat Favorable News Coverage Somewhat Unlikely to Affect Halyard Health (HYH) Share Price

News coverage about Halyard Health (NYSE:HYH) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Halyard Health earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical instruments supplier an impact score of 45.9619205610474 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Halyard Health (NYSE HYH) opened at $46.25 on Tuesday. The stock has a market capitalization of $2,196.33, a price-to-earnings ratio of 27.69, a P/E/G ratio of 5.48 and a beta of 1.60. Halyard Health has a 52 week low of $35.24 and a 52 week high of $50.99. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.74 and a current ratio of 2.98.

How to Become a New Pot Stock Millionaire

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.23. The company had revenue of $428.10 million during the quarter, compared to analyst estimates of $413.94 million. Halyard Health had a return on equity of 6.98% and a net margin of 5.82%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company earned $0.50 earnings per share. equities analysts expect that Halyard Health will post 0.96 EPS for the current fiscal year.

A number of equities analysts have recently commented on the company. ValuEngine raised Halyard Health from a “hold” rating to a “buy” rating in a report on Wednesday, February 28th. Zacks Investment Research lowered Halyard Health from a “buy” rating to a “hold” rating in a research note on Thursday, February 1st. Finally, TheStreet raised Halyard Health from a “c+” rating to a “b” rating in a research note on Monday, December 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Halyard Health currently has an average rating of “Buy” and a consensus price target of $49.33.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Halyard Health (HYH) Share Price” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Insider Buying and Selling by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with's FREE daily email newsletter.

Leave a Reply